AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis

Published:2022-12 Issue: Volume:113 Page:109370
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Yang Shuyue,Song Dezhi,Wang Ziyi,Su Yuangang,Chen Junchun,Xian Yansi,Huang Jian,Li Jing,Xu Jiake,Zhao Jinmin,Liu Qian

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference48 articles.

1. Osteoporosis;Compston;The Lancet,2019

2. Osteoporosis: now and the future;Rachner;The Lancet,2011

3. RANKL as a target for the treatment of osteoporosis;Matsumoto;J. Bone Miner. Metab.,2021

4. Novel population of human monocyte and osteoclast progenitors from pluripotent stem cells and peripheral blood;Root;Blood Adv.,2021

5. Osteoclasts: more than 'bone eaters';Charles;Trends Mol. Med.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress of ATM inhibitors: Opportunities and challenges;European Journal of Medicinal Chemistry;2024-11

2. Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL‐induced activation of NF‐κB and MAPK signaling pathways and ROS;Phytotherapy Research;2024-08-04

3. ROS-scavenging bioactive scaffold orchestrates bone regeneration for osteoporotic bone defect repair;Composites Part B: Engineering;2024-07

4. Glycogen Synthase Kinase-3 Beta (GSK3β) as a Potential Drug Target in Regulating Osteoclastogenesis: An Updated Review on Current Evidence;Biomolecules;2024-04-21

5. The cross-talk between macrophages and tumor cells as a target for cancer treatment;Frontiers in Oncology;2023-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3